hVIVO plc (AIM:HVO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
16.25
-0.38 (-2.26%)
Apr 17, 2025, 4:19 PM GMT+1
Market Cap 110.56M
Revenue (ttm) 67.21M
Net Income (ttm) 17.45M
Shares Out 680.37M
EPS (ttm) 0.03
PE Ratio 6.45
Forward PE 11.13
Dividend 0.00 (1.23%)
Ex-Dividend Date May 15, 2025
Volume 685,558
Average Volume 1,976,522
Open 16.51
Previous Close 16.63
Day's Range 16.00 - 17.00
52-Week Range 12.60 - 31.00
Beta 1.34
RSI 56.94
Earnings Date Apr 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19,... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yamin Khan
Employees 274
Stock Exchange London Stock Exchange AIM
Ticker Symbol HVO
Full Company Profile

Financial Performance

Financial Statements

News

Cathal Friel to step down as HVivo chairman

Cathal Friel, the co-founder of pharmaceutical services firm HVivo, formerly Open Orphan, is to step down as chairman of the group.

10 days ago - Independent Ireland

Half Year 2024 hVIVO PLC Investor Presentation Transcript

Half Year 2024 hVIVO PLC Investor Presentation Transcript

7 months ago - GuruFocus

Earnings rise 68pc at pharmaceutical services firm Hvivo

Pharmaceutical services firm Hvivo, formerly Open Orphan, has recorded a 67.6pc jump in earnings in the first six months of the year.

7 months ago - Independent Ireland